ArticleBlood2019
Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Radiation exposure of breast tissue in lymphoma radiotherapy: a systematic review of breast dose metrics published since 2000.Acta oncologica (Stockholm, Sweden) · 2025Pooled it
- Cancer Effects of Low to Moderate Doses of Ionizing Radiation in Young People with Cancer-Predisposing Conditions: A Systematic Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Pooled it
- Improving prediction accuracy of radiation-induced temporal lobe injury in nasopharyngeal carcinoma using ADC-based deep learning and dosiomics.BMC cancer · 2026Article
- Recent strategies in diagnosis, screening, prevention, and treatment of breast cancer in young women.Discover oncology · 2025Review
- Genetic and epigenetic bases of long-term adverse effects of childhood cancer therapy.Nature reviews. Cancer · 2025Review
- Impact of secondary hematologic malignancies on prognosis of Hodgkin's lymphoma survivors.Frontiers in oncology · 2025Article
- Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors.Nature medicine · 2024Article
- Correlation study of malignant lymphoma and breast Cancer in different gender European populations: mendelian randomization analysis.BMC genomic data · 2023Article
- Regulation mechanism and pathogenic role of lncRNA plasmacytoma variant translocation 1 (Genes & diseases · 2023Review
- Evaluation of polygenic risk score for risk prediction of gastric cancer.World journal of gastrointestinal oncology · 2023Review
- Germline risk factors for second malignant neoplasms after treatment for pediatric hematologic malignancies.Hematology. American Society of Hematology. Education Program · 2022Article
- Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.European journal of endocrinology · 2022Review
- Article
- Radiation increases COL1A1, COL3A1, and COL1A2 expression in breast cancer.Open medicine (Warsaw, Poland) · 2022Article
- Screening through Temperature and Thermal Pattern Analysis in DMBA - Induced Breast Cancer in Wistar Rats.Journal of biomedical physics & engineering · 2021Article
- The Future of Childhood Cancer Survivorship: Challenges and Opportunities for Continued Progress.Pediatric clinics of North America · 2020Review
- Individual response of humans to ionising radiation: governing factors and importance for radiological protection.Radiation and environmental biophysics · 2020Review
- Current and coming challenges in the management of the survivorship population.Seminars in oncology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
30 authors at 16 institutions in 4 countries.
Annemieke W J Opstal-van WindenDepartment of Epidemiology and Biostatistics.
Hugoline G de HaanDepartment of Epidemiology and Biostatistics.ORCID 0000-0003-1126-4776
Michael HauptmannDepartment of Epidemiology and Biostatistics.
Marjanka K SchmidtDepartment of Epidemiology and Biostatistics.ORCID 0000-0002-2228-429X
Annegien BroeksDivision of Molecular Pathology, Core Facility Molecular Pathology and Biobanking, and.
Nicola S RussellDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Cécile P M JanusDepartment of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Augustinus D G KrolDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Frederieke H van der BaanDepartment of Epidemiology and Biostatistics.
Marie L De BruinDepartment of Epidemiology and Biostatistics.ORCID 0000-0001-9197-7068
Anna M van EggermondDepartment of Epidemiology and Biostatistics.
Joe DennisCenter for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-4591-1214
Hoda Anton-CulverDepartment of Epidemiology, University of California Irvine, Irvine, CA.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Elinor J SawyerInnovation Hub, Guy's Cancer Centre, King's College London, London, United Kingdom.
Angela CoxSheffield Cancer Research, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.
Peter DevileeDepartment of Pathology and.
Maartje J HooningDepartment of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Julian PetoDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Fergus J CouchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Paul PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, and.ORCID 0000-0001-8494-732X
Nick OrrThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
Douglas F EastonCenter for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Berthe M P AlemanDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Louise C StrongMD Anderson Cancer Center, Houston, TX.
Smita BhatiaInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.
Rosie CookeDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
Leslie L RobisonDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN; and.
Anthony J SwerdlowDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
Flora E van LeeuwenDepartment of Epidemiology and Biostatistics.
Cancer Research And Biostatistics · USInstitute of Cancer Research · GBUniversity of Cambridge · GBErasmus MC Cancer Institute · NLLeiden University Medical Center · NLThe Netherlands Cancer Institute · NLKing's College London · GBLondon School of Hygiene & Tropical Medicine · GBMayo Clinic in Arizona · USSt. Jude Children's Research Hospital · USThe University of Texas MD Anderson Cancer Center · USUniversity of Alabama at Birmingham · USUniversity of California, Irvine · USUniversity of Copenhagen · DKUniversity of Southern California · USYorkshire Cancer Research · GB
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MMach-LETSGO: Machine-LEarning of Treatment, Survey, and Genetics towards Obtaining Correct Classification of Chronic Conditions in Adult Survivors in the Childhood Cancer Survivor Study - CCSS SupplU24CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Gregory Armstrong · 1999 to 2026
$96.7MCancer Research UK 10119Cancer Research UK 10124Cancer Research UK 16561Medical Research Council MC_PC_14105NCI NIH HHS P30 CA021765NCI NIH HHS U24 CA055727
Abstract
Female Hodgkin lymphoma (HL) patients treated with chest radiotherapy (RT) have a very high risk of breast cancer. The contribution of genetic factors to this risk is unclear. We therefore examined 211 155 germline single-nucleotide polymorphisms (SNPs) for gene-radiation interaction on breast cancer risk in a case-only analysis including 327 breast cancer patients after chest RT for HL and 4671 first primary breast cancer patients. Nine SNPs showed statistically significant interaction with RT on breast cancer risk (false discovery rate, <20%), of which 1 SNP in the
Indexed as
Genetic Predisposition to DiseaseAdultAgedAged, 80 and overBreast NeoplasmsCancer SurvivorsCase-Control StudiesFemaleGenotypeHodgkin DiseaseHumansMiddle AgedNeoplasms, Radiation-InducedNeoplasms, Second PrimaryOdds RatioPolymorphism, Single Nucleotide
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.